Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MSTT1041A (Astegolimab) or UTTR1147A in patients with severe COVID-19 pneumonia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• MSTT1041A (Astegolimab) (astegolimab)
• UTTR1147A (null)

Snippet

Sponsor: Genentech, Inc. | Conditions: COVID-19 Pneumonia | Phase 2 | Status: COMPLETED | Results posted: 2022-01-10